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ABSTRACT
MicroRNAs (miRNAs) are short noncoding RNAs, which
post-transcriptionally regulate gene expression. miRNAs
are transcribed as precursors and matured to active forms
by a series of enzymes, including Dicer. miRNAs are im-
portant in governing cell differentiation, development, and
disease. We have recently developed a feeder- and serum-
free protocol for direct derivation of endothelial cells
(ECs) from human embryonic stem cells (hESCs) and pro-
vided evidence of increases in angiogenesis-associated
miRNAs (miR-126 and -210) during the process. However,
the functional role of miRNAs in hESC differentiation to
vascular EC remains to be fully interrogated. Here, we
show that the reduction of miRNA maturation induced by
Dicer knockdown suppressed hES-EC differentiation. A
miRNA microarray was performed to quantify hES-EC
miRNA proﬁles during deﬁned stages of endothelial differ-
entiation. miR-99b, -181a, and -181b were identiﬁed as
increasing in a time- and differentiation-dependent man-
ner to peak in mature hESC-ECs and adult ECs. Aug-
mentation of miR-99b, -181a, and -181b levels by
lentiviral-mediated transfer potentiated the mRNA and
protein expression of EC-speciﬁc markers, Pecam1 and
VE Cadherin, increased nitric oxide production, and
improved hES-EC-induced therapeutic neovascularization
in vivo. Conversely, knockdown did not impact endothelial
differentiation. Our results suggest that miR-99b, -181a,
and -181b comprise a component of an endothelial-
miRNA signature and are capable of potentiating EC
differentiation from pluripotent hESCs. STEM CELLS
2012;30:643–654
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INTRODUCTION
MicroRNAs (miRNAs) are highly conserved, short noncoding
RNA molecules of approximately 22 nucleotides in length in
their mature form. miRNAs originally reside in the nucleus as
RNA polymerase II primary miRNA (pri-miRNA) transcripts
[1]; thereafter, they are processed in two steps. Within the nu-
cleus, pri-miRNAs are processed into approximately 70–100
nucleotide hairpin-shaped precursors known as pre-miRNAs
by Drosha, which form complexes with a double-stranded
RNA-binding domain protein, DGCR8/Pasha [2, 3], before
being transported to the cytoplasm via an Exportin-5-
and Ran-GTP-dependent mechanism [4]. Once in the cyto-
plasm, the double-stranded ribonuclease, Dicer, cleaves the
pre-miRNAs to yield approximately 20–22 base pair mature
miRNA duplexes [5]. The duplex is incorporated into the
effector ribonucleic acid-induced silencing complex (RISC)
where the duplex is unwound to form a mature single-
stranded miRNA. The mature miRNA strand that is incorpo-
rated in the RISC binds to the 30 untranslated region and
more rarely to other regions of speciﬁc target mRNAs through
a perfect or near-perfect complementary match to block trans-
lation or cleaves the mRNA [6, 7] (reviewed in [8–10]).
Pluripotent stem cells can be directly differentiated toward
endothelial cell (EC) lineages [11] and may be used to gener-
ate a large supply of transplantable, healthy, functional cells
for repair of ischemic tissues. However, the control of the
intricate transcriptional events controlling pluripotent stem
cell to vascular EC differentiation remains to be fully
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interrogated. Pluripotent human embryonic stem cells (hESCs)
are reported to express a unique panel of miRNAs, including
the miR-302 cluster and miR-371/372/373 cluster [12, 13].
The expression of these pluripotency-associated miRNAs is
suppressed upon differentiation with concordant induction of
differentiation-speciﬁc miRNAs, namely miR-145 and Let7
[14, 15]. Indeed, it has recently been demonstrated that over-
expression of the miR-302 cluster can facilitate reprogram-
ming of somatic cells to pluripotency [16]. We believe that
pluripotent stem cells, both hESCs and induced pluripotent
stem cells, may provide a unique model system through
which the study of miRNA function during early stages of
lineage development and commitment can be quantiﬁed.
Initial evidence for contribution of miRNAs in EC devel-
opment and differentiation was provided by the observation
that Dicer knockout mice have an embryonic lethal phenotype
[17]. In fact, Dicer knockout embryos suffered severely dis-
rupted blood and vessel formation accompanied with retarded
expression of early endothelial markers VEGF, FLT1, KDR,
and tie1 [17]. These results were supported in vitro by dem-
onstration that Dicer is a prerequisite for EC function [18,
19]. However, endothelial-restricted tissue-speciﬁc deletion of
Dicer demonstrated that endothelial progenitor cells devel-
oped, albeit with compromised blood circulation, and a lack
of embryonic lethal phenotype was observed in both zebraﬁsh
[20] and mice [21]. These results suggest that miRNAs may
not be pivotal in endothelial differentiation and developmental
angiogenesis. This is compounded by the failure to date in
using a speciﬁc miRNA deletion to evoke fully penetrant em-
bryonic lethality in mice. On other hand, murine ESCs sub-
jected to loss of global miRNAs via Dicer or Drosha knock-
down exhibit reduced self-renewal and proliferative
capabilities with marked defects in differentiation [22, 23];
however, this has yet to be reported in hESCs. To date, only
a small number of studies have focused on the involvement
of angiogenesis-associated miRNAs in EC differentiation
from pluripotent stem cells. This is in agreement with current
literature reporting that despite the demonstration of differen-
tially expressed miRNAs during endothelial differentiation in
vitro, none of the miRNAs so far have been reported to
directly govern EC fate decisions [24, 25]. For example, miR-
126 was identiﬁed as enriched in ECs derived from mouse
ESCs and in developing mouse embryos [26, 27], with knock-
down studies in zebraﬁsh resulting in hemorrhage and loss of
vascular integrity [26, 27]. Indeed, previous studies in zebra-
ﬁsh have provided evidence that miR-126 provides a crucial
link between ﬂow and Vegf signaling to promote angiogene-
sis, by acting downstream of klf2a to drive shear ﬂow-stimu-
lated angiogenesis via repression of spred1 and pik3r2 [28].
Furthermore, targeted deletion of miR-126 evoked defects in
EC function and resulted in leaky vessels in mice, but did not
evoke full embryonic lethality [29], suggesting that the endo-
thelial-speciﬁc miR-126 does not control EC differentiation
but does control cell function [25]. This hypothesis is further
ratiﬁed with results from a previous study reporting that
miRNA-126 overexpression in pluripotent SCs prevented dif-
ferentiation toward the EC lineage [27], indicating that miR-
126 does not command early EC lineage commitment but is
induced by vascular differentiation.
We have recently described the increased expression of
angiogenesis-associated miRNAs (miR-126, -130a, -133a,
-133b, and -210) [25, 30] and decrease in antiangiogenic miR-
NAs (miR-20a, -20b, -221, and -222) [31] during our feeder-
and serum-free-directed hESC-EC differentiation protocol
[11]. To date, despite the demonstration of miRNA regulation
in a myriad of vascular biology events and the mapping of
initial stages of mesoderm commitment [32], no individual
miRNAs have been shown to directly control mesoderm to
vascular EC fate decisions. There is still insufﬁcient evidence
demonstrating miRNA involvement in early human develop-
ment of vascular cells, how they control mesoderm-EC fate
commitment, and the mechanisms involved in these differen-
tiation processes.
In this study, we analyzed early stages of EC lineage
commitment and the miRNA-ome to identify miRNAs inte-
gral to human EC development. We identiﬁed miR-99b,
-181a, and -181b as miRNAs enriched in hES-ECs differenti-
ated from pluripotent stem cells and conﬁrmed their expres-
sion in adult venous ECs. We interrogated their role in differ-
entiation by modulating their expression and directing
differentiation to EC lineage. Overexpression of the aforemen-
tioned miRNAs augmented the differentiation potential of plu-
ripotent cells and improved their potential for therapeutic
angiogenesis in a mouse model of limb ischemia. The results
herein demonstrate that miRNA regulation of development to
speciﬁed lineages is a potential target for optimizing the gen-
eration of proangiogenic vascular ECs for regenerative
medicine.
MATERIALS AND METHODS
See also Supporting Information Detailed Methods online for fur-
ther reference.
Cell Lines and Culture Conditions
The hESC lines H1, H9 (WiCell Research Institute, Madison,
WI, http://www.wicell.org), and 461 (Cellartis, Dundee, U.K.)
were cultured in a feeder-free system [11]. Endothelial differen-
tiation was induced as previously described [11]. Hematopoietic
and neural progenitor cells were generated from H1 hESC as pre-
viously described [33, 34]. The cells were harvested at deﬁned
time points as indicated and expressed characteristic markers of
hESC-derived hematopoiesis (hES-hematopoietic progenitor cell
[HPC] CD34 [41%] and CD45 [54%]) as analyzed by ﬂow cyto-
metric analysis. Samples from neuronal differentiations (hES-neu-
ral) were taken at day 10 for consistency with other miRNA anal-
yses at this time point. Cultures performed in this lineage
differentiation display characteristic early neural rosette morphol-
ogy and later entangled projections and positive staining for
PAX6 and nestin as previously described [34]. Primary human sa-
phenous vein ECs (SVEC) were cultured in endothelial differen-
tiation media supplemented with 20% fetal bovine serum (FCS)
(PAA Laboratories, Somerset, U.K., http://www.paa.at).
HEK293T cells (ATCC, Teddington, U.K., http://www.atcc.org)
were maintained in Dulbecco’s modiﬁed Eagle’s medium (Invi-
trogen, Paisley, U.K., http://www.invitrogen.com) supplemented
with 10% heat-inactivated FCS (Invitrogen), penicillin (50 lg/ml;
Invitrogen), streptomycin (50 lg/ml; Invitrogen), L-glutamate
(2 mM; Invitrogen), and sodium pyruvate (1 mM; Invitrogen).
All cells were cultivated at 37C in a humidiﬁed atmosphere con-
taining 5% CO2.
Lentiviral Vectors and hESC Infection
Lentiviral (LV) vectors were produced as previously described
[35]. LV titers were ascertained by TaqMan quantitative real-time
polymerase chain reaction (Q-RT PCR) [11, 36]. For infection, 2
 104 cells were transduced with a multiplicity of infection
(MOI) of 25. Cells were incubated in pluripotent maintenance
media containing LV particles and 4 lg/ml polybrene (Sigma-
Aldrich, Dorset, U.K., http://www.sigmaaldrich.com) for 18 hours
at 37C in a humidiﬁed atmosphere containing 5% CO2. LV par-
ticles were removed, and media were replaced with fresh pluripo-
tent maintenance media for an additional 24 hours to permit cell
recovery.
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Overexpression of miRNAs
The pre-miRNA sequence of -99b, -181a, or -181b (Supporting
Information Table 1) was cloned directly into the lentiviral con-
struct (pLNT)/spleen focus-forming virus (SFFV)-multiple clon-
ing site (MCS), plasmid (kind gift from Prof. Adrian J. Thrasher,
ICH, UCL, London, U.K.) to obtain the construct pLNT/SFFV-
premiR. Suppression of miRNA function was achieved by a
miRNA Zip plasmid speciﬁc for miR-99b, -181a, and -181b
(Cambridge Bioscience, Cambridge, U.K., http://www.bioscien-
ce.co.uk). Dicer knockdown was achieved with pSicoR human
Dicer plasmid (kind gift from Prof. Richard I. Gregory, Harvard,
MA) [37].
miRNA Microarray
The miRNA expression proﬁle of hESC-ECs was determined by
two-channel miRNA microarray analysis using the human
miRNA array (LC Sciences, Houston, TX) based on miRBase,
version 10.1 (Sanger miRBase) (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc ¼ GSE33675). Supporting Information Figure
S1 depicts the experimental design of the miRNA microarray. To
assess the statistical signiﬁcance of intergroup differences, the
empirical Bayes method implemented in the limma R package
was used [38]. Signiﬁcance was assessed using the false discov-
ery rate multiple rate multiple testing correction method, with a
false discovery rate cutoff of 5%.
TaqMan Q-RT PCR Analysis of Mature
miRNAs and mRNAs
Total cellular RNA was isolated using miRNAeasy Mini Kit
(Qiagen, Crawley, U.K., http://www.qiagen.com). Total RNA was
reverse transcribed using speciﬁc miRNA primers provided with
TaqMan miRNA assays or reverse transcribed using random pri-
mers for mRNA expression analysis. Human miRNAs were ana-
lyzed using TaqMan miRNA assays (Applied Biosystems). First-
Choice Human Total RNA Survey Panel (Applied BioSystems,
Foster City, CA, http://www.appliedbiosystems.com) was ana-
lyzed to determine miRNA expression.
Northern Blotting
Total RNA (10 lg) was resolved in a denatured 15% polyacryl-
amide gel and then electrotransferred to a Hybond nylon mem-
brane (GE Healthcare, Buckinghamshire, U.K., http://gehealthcare.
com). Following carbodimide-mediated cross-linking, membranes
were hybridized with digoxigenin (DIG)-labeled locked nucleic
acid (LNA) probes (Exiqon, Woburn, MA) at 60C overnight.
After posthybridization washes, membranes were incubated with
anti-DIG-alkaline phosphatase (AP) antibody (1:10,000; Roche,
Welwyn Garden City, U.K., http://www.roche-applied-science.
com) in 1% blocking reagents (Roche), and signal was visualized
using CDP-Star (Sigma-Aldrich) according to the manufacturer’s
instructions.
Western Blotting
Total protein (20 mg) from each sample was loaded onto a pre-
cast 4%–20% gradient Tris-glycine gel (Novex; Invitrogen),
resolved at 100 V for 1 hour, and then electrotransferred onto
polyvinylidene diﬂuoride membranes. Blots were blocked for 1
hour at 25C in Tris-buffered saline plus Tween 20 plus 3%
milk. Blots were incubated with mouse monoclonal anti-human
Dicer (1:1000; Abcam, Cambridge, U.K. http://www.abcam.com)
or mouse monoclonal anti-human glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (1:1,000, Sigma-Aldrich) followed by
goat polyclonal antimouse IgG (1:10,000; Sigma-Aldrich) conju-
gated to horseradish peroxidase. Blots were visualized using the
enhanced chemiluminescence method (ECL Kit; Amersham Bio-
sciences, Little Chalfont, U.K., http://www. amersham.com) fol-
lowing the manufacturer’s instructions. Membranes were reprobed
for GAPDH to correct for protein loading.
Fluorescence-Activated Cell Sorting
Cells were incubated with mouse IgG1 monoclonal anti-human
CD31-ﬂuorescein isothiocyanate (FITC) (BD Pharmingen, Oxford,
U.K., http://www.bdbiosciences.com) and mouse IgG2b monoclo-
nal anti-human VE Cadherin-phycoerythrin (PE) (R&D Systems,
Abingdon, U.K., http://www.rndsystems.com) or species-matched
isotype control (BD Pharmingen). Cellular ﬂuorescence was
detected in a BD Caliber Flow Cytometer.
Assessment of Nitric Oxide Production
Quantiﬁcation of nitric oxide (NO) production was conducted as
according to the manufacturer’s instructions (Enzo Life Sciences
(U.K) Ltd., Exeter, U.K., http://www.enzolifesciences.com).
Cell Transplantation Study
The experiments involving mice were performed in accordance
with the Guide for the Care and Use of Laboratory Animals pre-
pared by the Institute of Laboratory Animal Resources and covered
by U.K. Home Ofﬁce licenses. Unilateral hind limb ischemia was
induced in immunocompromised CD1-Foxn1nu mice (Charles
River, U.K.), as described [11, 39]. hESC-ECs differentiated for 14
days (106 cells in 15 ll of culture medium) infected with control LV
or pLNT/SFFV-premiR-99b, -181a, or -181b (n ¼ 10 mice/group)
were injected immediately after induction of ischemia in three equi-
distant sites of the ischemic adductor muscle along the projection of
the femoral artery. Foot blood ﬂow was measured at basal, 7, 14,
and 21 days after ischemia by using a high-resolution laser Doppler
imager system (MoorLDI2, Moor Instruments, Axminster, U.K.,
http://www.moor.co.uk). At 21 days postsurgery, the limbs of termi-
nally anesthetized mice were perfusion-ﬁxed and ischemic adductor
muscles harvested. Capillary density was measured in transverse
muscular section following staining with biotinylated lectin (isolec-
tin; 1:100, Invitrogen) to recognize ECs [40, 41].
Statistical Analysis
Prior to any statistical analysis, data were tested for and shown to
exhibit Gaussian distribution. Gaussian distribution was deter-
mined by applying the Shapiro–Wilk normality test to the data.
Where appropriate, values were presented as means 6 SEM.
RESULTS
Knockdown of Dicer Reduces hESC Differentiation
to Endothelial Lineage
We ﬁrst evaluated regulation of Dicer expression during hES-
EC differentiation in hESC lines SA461 and H1. Dicer was
increased 130-fold after 4 days, 123-fold after 10 days, and
62-fold after 14 days of differentiation, when compared with
pluripotent samples (Fig. 1A). LV-mediated knockdown of
Dicer mRNA expression in hESCs was conﬁrmed by compar-
ison with uninfected and scrambled LV-short hairpin rna
(ShRNA) controls and was sustained throughout a 14-day pe-
riod. No signiﬁcant difference was observed in cells infected
with a LV encoding a scramble sequence, when compared
with uninfected controls at any time point, whereas LV-Dicer
shRNA evoked a signiﬁcant suppression of Dicer mRNA at 4,
10, and 14 days postinduction of differentiation, when com-
pared with uninfected controls (Fig. 1B). Protein expression
of Dicer paralleled the mRNA expression proﬁle. Although
no notable difference was observed between uninfected and
scramble sequence control samples (Fig. 1C), Dicer protein
expression was reduced substantially at all times in samples
subjected to LV-mediated Dicer knockdown (Fig. 1C).
Morphological analysis of these cells at days 4, 10, and
14 of differentiation demonstrate that reduction of Dicer was
correlated with lack of morphological changes indicative of
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EC differentiation, namely the acquisition of a cobblestone-
like morphology, as observed in all control cells (Fig. 2A).
Dicer knockdown also suppressed expression of classic endo-
thelial marker genes, VE Cadherin and Pecam1, by TaqMan
(Fig. 2B) and ﬂuorescence-activated cell sorting (FACS) anal-
ysis (Fig. 2C). Dicer knockdown abrogated mRNA expression
of VE Cadherin (4.8- and 2.7-fold) and Pecam1 (7- and 3.5-
fold) at days 10 and 14 postinduction of differentiation (Fig.
2B). We also used a panel of EC fate markers to assess the
impact of Dicer knockdown. We observed the induction of all
endothelial lineage markers in control samples but observed a
propensity for expression of the arterial marker, Ephrin B1
(125-fold induction), and venous markers, NRP2 (115-fold
induction) and NR2F2 (270-fold induction) at day 14 of differ-
entiation, when compared with pluripotent samples (Fig. 3A).
LV-mediated Dicer knockdown prevented the differentiation to
arterial, venous, or lymphatic lineages, as determined by Taq-
Man analysis (Fig. 3A). Disruption of the miRNA biogenesis
pathway also reduced NO production threefold in cells differ-
entiated for 14 days, when compared with controls (Fig. 3B).
Global miRNA Proﬁling of hESC-Derived ECs
To assess changes in the miRNA-ome during the early stages
of endothelial differentiation, the expression of 374 mature
human miRNAs at days 2, 4, and 10 of endothelial differen-
tiation (vs. pluripotent time-matched samples) in SA461 hESC
line was analyzed in a two-channel microarray (Supporting In-
formation Fig. S1A and http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token ¼ vtsddsqskeiwcvc&acc ¼ GSE33675).
Expression of the pluripotency-associated miRNAs miR-302a–d,
-372, and -373 was signiﬁcantly suppressed with progression of
differentiation (Supporting Information Fig. S1B, S1C). The
expression of miR-99b, -181a, and -181b was, in contrast,
increased in a time- and differentiation-dependent manner com-
pared with time-matched pluripotent samples (Fig. 4A). We vali-
dated the expression proﬁles in three hESC lines, SA461 (Fig.
4A), H1, and H9 cells (Supporting Information Fig. S2), directed
to EC differentiation more than 21 days, when compared with
time-matched pluripotent controls and observed good concord-
ance between microarray, Q-PCR, and Northern blot analysis
(Fig. 4A). We next assessed whether expression of miR-99b,
-181a, and -181b would be induced in hESC-derived hematopoi-
etic cells (mesoderm lineage) or neural cells (ectoderm lineage).
hES-ECs expressed signiﬁcantly elevated levels of mature
miRNA than pluripotent cells or their time-matched hematopoi-
etic or neural counterparts for all three miRNAs (Fig. 4B) con-
ﬁrming the selectivity to the endothelial lineage in comparison
with both alternate lineages evaluated.
Validation of EC Differentiation-Associated
miRNAs in Adult ECs and Tissues
We next assessed the expression of miR-99b, -181a, and
-181b in adult SVECs in comparison with SA461 hESC-ECs
differentiated for 10 days and observed no differences in
miR-99b expression between the aforementioned cell types
(Supporting Information Fig. S3A). However, we did observe
signiﬁcantly less miR-181a (twofold) and -181b (threefold)
expression in hESC-ECs differentiated for 10 days compared
with adult ECs (Supporting Information Fig. S3A). In addi-
tion, we assessed the expression of miR-99b, -181a, and
-181b across a panel of human tissues, when compared with
pluripotent hESCs. We noted that miR-99b, -181a, and -181b
were expressed in all tissues but that high expression was
detected in brain (miR-99b, -181a, and -181b), heart (miR-
99b, -181a, and -181b), and lung and thymus tissue (miR-
181a and -181b) (Supporting Information Fig. S3B).
Modulation of EC Differentiation-Associated
miRNAs Potentiates EC Differentiation
We sought to deﬁne the effect of miR-99b, -181a, and -181b
modulation on EC differentiation from pluripotency. To
achieve this, we used self-inactivating vesicular stomatitis vi-
rus-pseudotyped LV vectors to modulate miRNA expression
by infecting pluripotent SA461 and H1 hESCs prior to
directed EC differentiation. miR overexpression was achieved
by inducing expression of the pre-miR sequence or scramble
sequence control, using a MOI of 25. miR knockdown was
achieved by inducing expression of a miRZip antisense
miRNA RNA interference (RNAi) hairpin (that competitively
binds the endogenous miRNA target and inhibit its function)
or scramble sequence control, using a MOI of 25. Efﬁcient
modulation of each miRNA was conﬁrmed by TaqMan in
both hESC lines (Supporting Information Fig. S4). miRNA
overexpression potentiated mRNA expression of EC-speciﬁc
markers, Pecam1 and VE Cadherin, at days 10 and 14 of dif-
ferentiation, when compared with controls (Fig. 5A). FACS
analysis of Pecam1 and VE Cadherin demonstrated that H1
Figure 1. Lentiviral (LV)-mediated knockdown of Dicer in human
embryonic stem-endothelial cells (hES-ECs). (A): Dicer mRNA
expression during SA461 hES-EC differentiation. *Denotes signiﬁ-
cance, when compared with pluripotent D0 sample. þDenotes signiﬁ-
cance, when compared with D4 and D10 hES-EC sample. (B): Dicer
mRNA expression after LV-mediated knockdown. Pluripotent SA 461
hESCs (2  104) were transduced with a multiplicity of infection of 25
prior to directed EC differentiation. Pluripotent samples (black bar),
LV-shRNA SCR sequence (gray bar), and LV-shDicer sequence (white
bars). Data are given as the mean 6 SEM. *, p < .05; **, p < .01; ***,
p < .001 versus the time-matched uninfected sample. (C): Western
blot analysis of Dicer protein expression in SA461 hESCs. Abbrevia-
tions: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SCR,
scramble; shRNA, short hairpin RNA; UI, uninfected.
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hESCs are more refractory to endothelial differentiation than
SA461 hESCs, with 80% SA461 (mean ﬂuorescence intensity
(MFI): 14.0) and only 61% H1 (MFI: 9.0) cells expressing
one or both endothelial markers at day 14 (Fig. 5B). miR
overexpression elicited a greater effect in H1 cells, resulting
in a 33% (miR-99b, MFI: 27.5), 34% (miR-181a, MFI: 33.5),
and 33% (miR-181b, MFI: 28.9) increase in cells expressing
one or both Pecam1 and VE Cadherin at day 14 of
Figure 2. Dicer knockdown is correlated with lack of acquisition of endothelial cell (EC) phenotype. (A): Morphology of SA461 human em-
bryonic stem cells subjected to LV-mediated Dicer knockdown or SCR sequence control (multiplicity of infection 25). Control cells (UI and
SCR sequence samples) display morphological acquisition of a cobblestone-like appearance, typical of EC differentiation. Dicer knockdown pre-
vents the appearance of morphological changes indicative of EC differentiation. Scale bar ¼ 100 lm. (B): mRNA expression of VE Cadherin
and Pecam1 in SA461 cells subjected to LV-mediated Dicer knockdown or UI and SCR sequence controls. D0 ¼ white bars, D4 ¼ black bars,
D10 ¼ dark gray bars, and D14 ¼ light gray bars. Data are given as the mean 6 SEM. *, p < .05; ***, p < .001 versus the time-matched unin-
fected sample. (C): Fluorescence-activated cell sorting analysis of increasing positive expression of VE Cadherin (FL1) and Pecam1 (FL2)
observed in a time- and differentiation-dependent manner for more than 14 days of directed differentiation. LV-mediated Dicer knockdown
reduced the population expressing one or both markers. Abbreviations: LV, lentiviral; SCR, scramble; UI, uninfected; VE, vascular endothelial.
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differentiation (vs. uninfected and scramble sequence control
samples), when compared with a 4% (miR-99b, MFI: 15.34),
11% (miR-181a, MFI: 25.1), and 0% (miR-181b, MFI: 20.0)
increase in SA461 cells (Fig. 5B). Conversely, miR inhibition
did not reduce the population of cells expressing endothelial
markers in either cell line (Supporting Information Fig. S5B);
however, we did observe a signiﬁcant reduction in Pecam1
and VE Cadherin mRNA expression, signifying discordance
between transcript and protein expression proﬁles (Supporting
Information Fig. S5B).
We also assessed whether miRNA modulation would have
any effect on NO production of hESC-ECs differentiated for up
to 14 days. Overexpression of miR-99b, -181a, and -181b
evoked an increase in NO production in hES-ECs after 4 days of
differentiation, when compared with control samples. Overex-
pression of miR-99b and -181b also augmented NO production
at days 10 and 14, respectively (Fig. 5C). Conversely, inhibition
of miR-99b, -181a, and -181b evoked a reduction in NO produc-
tion, with suppression observed at day 14 (Supporting Informa-
tion Fig. S5C). No additive or synergistic effect on endothelial
marker expression or NO production was observed with combi-
natorial overexpression or knockdown of miR-99b, -181a, and -
181b together (Fig. 5, Supporting Information Fig. S5).
We next determined whether the modulation of miRNAs
miR-99b, -181a, and -181b would have an effect on the line-
age speciﬁcation of hESC-ECs. Overexpression of miR-99b
evoked a signiﬁcant induction of the arterial gene, Hey2, and
the lymphatic gene, FLT4. miR-99b overexpression also sup-
pressed expression of the lymphatic marker, podoplanin
(PDPN) (Fig. 6). Inhibition of miR-99b intriguingly also aug-
mented expression of PDPN and the arterial genes, Hey2 and
Jagged2, but suppressed expression of the arterial gene, Eph-
rin B2, and venous genes, EphB4 and NR2F2, when com-
pared with scrambled sequence control samples (Supporting
Information Fig. S6). Overexpression of miR-181a potentiated
the expression of all arterial genes analyzed, Ephrin B1, Eph-
rin B2, Hey2, and Jagged2 and the lymphatic gene, PDPN.
miR-181a overexpression also suppressed expression of NRP2
and Prox1, when compared with control samples (Fig. 6). In-
hibition of miR-181a induced expression of Prox1 and sup-
pressed expression of Ephrin B2, when compared with control
samples (Supporting Information Fig. S6). Overexpression of
miR-181b potentiated the expression of the lymphatic gene,
PDPN, but suppressed the expression of Ephrin B1 and
NRP2, as compared to scramble sequence control samples
(Fig. 6). Inhibition of miR-181b suppressed expression of the
arterial genes, Ephrin B1, Ephrin B2, and Hey2 and induced
expression of all lymphatic genes analyzed, FLT4, PDPN, and
Prox1, when compared with control samples (Supporting In-
formation Fig. S6). Changes in vascular bed genes were not
Figure 3. Dicer knockdown prevents the acquisition of vascular bed marker genes and reduces nitric oxide (NO) production. (A): mRNA expres-
sion of vascular bed marker genes in H1 human embryonic stem cells (hESCs). Expression of all vascular bed markers are induced with differen-
tiation in UI and SCR sequence controls but reduced with Dicer knockdown. D0 ¼ white bars, D4 ¼ black bars, D10 ¼ dark gray bars, and D14
¼ light gray bars. Data are given as the mean 6 SEM. *, p < .05; **, p < .01; ***, p < .001 versus the time-matched uninfected sample. (B):
NO production in D0 and D14 H1 hES-endothelial cells subjected to lentiviral-mediated Dicer knockdown or UI and SCR sequence controls. Dicer
knockdown suppresses NO production. Data are given as the mean 6 SEM. **, p < .01; ***, p < .001 versus the time-matched uninfected sample
or þþ, p < .01 versus pluripotent sample. Abbreviations: SCR, scramble; UI, uninfected.
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uniform throughout the duration of the differentiation time
course (Fig. 6 and Supporting Information Fig. S6).
To determine the therapeutic potential of miR-modiﬁed
hESC-ECs for vascular regeneration in vivo, day 14-differenti-
ated H1 hESC-ECs infected with pLNT/SFFV-green ﬂuores-
cent protein or pLNT/SFFV-premiR-99b, -181a, or -181b were
intramuscularly injected into the ischemic adductor muscle of
immunocompromised mice and hind limb blood ﬂow recovery
monitored for more than 21 days. Figure 7B shows representa-
tive Doppler images at day 21 postischemia. At 21 days post-
induction of ischemia, blood ﬂow to the ischemic foot was
improved by hESC-ECs overexpressing either miR-99b or
-181a, when compared with the virus control. A trend toward
improved blood ﬂow was observed with hESC-ECs overex-
pressing miR-181a; however, this did not attain statistical sig-
niﬁcance compared with virus control (Fig. 7A). In agreement
with improved blood perfusion data, transplantation of hESC-
EC subjected to miR-99b or -181b overexpression also
enhanced capillary density of the ischemic adductor at 21 days
postischemia, whereas miR-181a had no effect (Fig. 7C).
Figure 4. MicroRNA (miRNA) microarray validation of miRNA transcriptome at early time points of endothelial lineage speciﬁcation. (A): Taq-
Man and Northern blot validation of microarray expression. Expression of mature miR-99b, -181a, and -181b is induced in an endothelial differentia-
tion-speciﬁc manner, when compared with time-matched pluripotent samples in SA461 hESC line. Data are given as the mean 6 SEM. *, p < .05;
**, p < .01; ***, p < .001 versus the time-matched pluripotent sample. (B): Expression of miR-99b, -181a, and -181b in H1 pluripotent, hES-EC,
hES-HPC, and hES-neural cell. Data are given as the mean 6 SEM. *, p < .05; **, p < .01; ***, p < .001 versus pluripotent sample. þVersus the
time-matched differentiated sample. Abbreviations: EC, endothelial cell; hES, human embryonic stem; HPC, hematopoietic progenitor cell; RQ: rela-
tive quantiﬁcation.
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DISCUSSION
This study describes the identiﬁcation of three miRNAs that
are expressed upon differentiation of ECs from pluripotent
stem cells. We report that miRNA processing by Dicer is nec-
essary for endothelial differentiation, evidenced by Dicer
knockdown substantially reducing hESC differentiation to EC.
We analyzed early stages of EC lineage commitment and the
miRNA transcriptome to identify miR-99b, -181a, and -181b
speciﬁcally upregulated during differentiation. Moreover, we
report that augmentation of miRNAs by gene transfer can
potentiate the endothelial differentiation capacity in a hESC
line that evokes relatively poor differentiation to ECs. Finally,
we demonstrate that the transplantation of hESC-ECs overex-
pressing either miR-99b or -181b into the muscle of immuno-
deﬁcient mice subjected to hind limb ischemia promoted ther-
apeutic neovascularization and blood ﬂow recovery.
With respect to in vitro differentiation from pluripotent
stem cells, the role of miRNAs has been implicated in studies
using Dicer- or Drosha-deﬁcient mouse ESCs. Dicer- or Dro-
sha-deﬁcient ESCs were unable to generate mature miRNAs,
which subsequently impeded differentiation [23, 42, 43]; how-
ever, this has as yet not been reported in hESCs. We report
herein the ﬁrst demonstration that LV-mediated knockdown
of Dicer abrogated the potential of pluripotent hESCs to dif-
ferentiate to an EC lineage (Fig. 2) highlighting that the ca-
nonical biogenesis of mature miRNAs is likely required for
successful endothelial differentiation. Herein, we also report
that Dicer knockdown suppresses the production of NO in
hESC directed to EC lineage (Fig. 3). This is in agreement
with our previous data demonstrating a differentiation-speciﬁc
increase in EC marker gene expression concordant with a
functional EC phenotype in vitro and in vivo and the ability
to produce and respond to an NO stimulator [11]. Recent
additional studies have reported that abrogation of Dicer is ca-
pable of preventing ES differentiation toward other lineages
[44–48]. We have focused on hES-EC differentiation, but it is
likely that Dicer suppression would impair human pluripotent
cell differentiation to other lineages similar to murine ESCs.
Figure 5. Overexpression of miRNAs potentiates endothelial cell (EC) differentiation. (A): mRNA expression of VE Cadherin and Pecam1 in
H1 human embryonic stem cells (hESCs) subjected to lentiviral-mediated overexpression of miR-99b, 181a, 181b, all together (miR 3), or
UI and SCR sequence controls. (B): Fluorescence-activated cell sorting analysis of positive expression of VE Cadherin (FL1) and Pecam1 (FL2)
in hES-EC subjected to 14 days of directed differentiation. (C): Nitric oxide (NO) production in hES-ECs. miR-99b, 181a, 181b, all together
(miR 3), or overexpression potentiates NO production. Data are given as the mean 6 SEM. **, p < .01; ***, p < .001 versus the time-matched
uninfected sample or þþ, p < .01 versus pluripotent sample. D0 ¼ white bars, D4 ¼ black bars, D10 ¼ dark gray bars, and D14 ¼ light gray
bars. Abbreviations: SCR, scramble; UI, uninfected; VE, vascular endothelial.
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We reasoned that lineage-speciﬁc miRNAs must be proc-
essed and contribute to the master regulation of the earliest
stages of lineage speciﬁcation and commitment. We have pre-
viously demonstrated that the expression of angiogenesis-
associated mature miRNAs (miR-126, -130a, -133a, -133b,
and -210) was present at 10-day postdifferentiated functional
hES-ECs [11]. With this in mind, we sought to identify miR-
NAs expressed at earlier stages of lineage commitment to EC.
We differentiated hESCs toward an EC lineage using our pre-
viously reported serum- and feeder-free protocol [11]. This
protocol circumvented the need for an embryoid body forma-
tion with cells differentiating in a uniform manner, thereby
providing a unique opportunity to analyze the miRNA compo-
nent at early stage of lineage commitment without the need to
deplete cells from the other germ lineages. In agreement with
previous studies, we identiﬁed the expression of the pluripo-
tency-associated miRNA clusters 302 and 372/373 as present
in our pluripotent hESC samples [12, 13]. We also validated
the substantial loss of differentiation-associated miR-302a–d,
-372, and -373 in agreement with previous studies [12, 13].
We identiﬁed and validated the expression of miR-99b, -181a,
and -181b in the early stages of EC differentiation from three
pluripotent hESC lines. miR-99b is an intergenic miRNA and
transcribed in a cluster with miR-125a and Let7e. This is in
agreement with our previous ﬁnding that members of the Let7
family were induced upon directed differentiation to ECs
[11]. Furthermore, we also identiﬁed miR-125a-5p as being
highly expressed in the early stage of EC lineage speciﬁcation
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token ¼ vtsdd
sqskeiwcvc&acc¼GSE33675). miR-181a and -181b are both
predicted to be expressed from two genomic hairpin loci,
miR-181a/b-1 and -181a/b-2 (www.mirbase.org). The mature
sequences are identical regardless of cleavage by Dicer from
pre-miR-181a/b-1 or -2. miR-181a and -181b are both intra-
genic, but the genes that they reside in currently have no
known function. We subsequently conﬁrmed the expression of
miR-99b, -181a, and -181b in adult human SVECs, with no
notable differences observed in mature miR-99b expression
levels between the adult ECs and SA461 hES-ECs differenti-
ated for 10 days (Supporting Information Fig. S3A). We did
observe signiﬁcantly less miR-181a and -181b between day
10-differentiated hES-ECs and adult SVECs although levels
at day 10 were easily detected by Northern blot analysis (Sup-
porting Information Fig. S3A). The identiﬁcation of miR-99b
[49], -181a [50], and -181b [19] is consistent with previous
miR proﬁling data performed in ECs, but to our knowledge
none have been associated with differentiation from pluripo-
tency to endothelial lineage. miR-181b has also previously
been identiﬁed as expressed in CD34þ cells during hemato-
poietic differentiation from pluripotent cells [51]. CD34 is
expressed on mesoderm and early ECs [52] providing further
evidence for a miR-181b role in early-stage commitment to
EC differentiation. In addition, we have demonstrated that
there is very low expression of miR-99b, -181a, and -181b in
cells that are differentiated toward neural (ectopic) or hemato-
poietic (mesoderm) lineages; however, this is greatly potenti-
ated in cells directed toward EC lineage (Fig. 4). To this end,
it remains likely that miR-99b, -181a, and -181b are also
expressed to a certain extent on cells of mesoderm origin, for
example, hematopoietic cells owing to the common precursor
that HSC and EC develop through [53]. However, this does
highlight that in some capacity miR-99b, -181a, and -181b
could be acting to promote cell cycle and generic differentia-
tion progression from the pluripotent state, as previously
reported for miR-195 and -372 [54].
We sought to determine whether modulation of miR-99b,
-181a, or -181b would elicit any effect of the differentiation
capacity of pluripotent stem cells toward an EC lineage.
Overexpression of the premiR sequence for miR-99b, -181a,
and -181b induced a signiﬁcant increase in mature miR-99b,
-181a, and -181b expression, respectively, thus signifying efﬁ-
cient processing of pre-miRNAs (Supporting Information Fig.
S4). miR-99b and -181a augmentation was capable of signiﬁ-
cantly increasing the vascular EC marker genes, Pecam1 and
VE Cadherin, at the transcript level in both hESC lines (Fig.
6). No additional beneﬁt was observed by overexpressing all
three miRNAs in combination. Furthermore, we report that
upon analysis of the cell population expressing both proteins
and ability to produce NO, we noted that there was an
increased response to miRNA overexpression for all three
miRNAs, including miR-181b that did not evoke a signiﬁcant
response at the mRNA level, in the H1 hESC line, when com-
pared with SA461 cells (Fig. 5). This was encouraging as we
had also observed a substantial difference in the baseline efﬁ-
ciency of the hESC lines to acquire an endothelial phenotype
(expression of one or both markers), with H1 cells proving
more refractory than SA461 cells when exposed to our EC
differentiation protocol (Fig. 5), in agreement with a previous
study examining the differentiation heterogeneity between lines
[55]. We acknowledge that expression of one marker alone is
not conclusive demonstration of EC lineage, but it may indicate
Figure 6. Expression of vascular bed markers after microRNA
overexpression modulation. Fold expression of vascular bed marker
genes in H1 human embryonic stem cells relative to time-matched
lentiviral (LV)-shRNA scramble sequence controls. Data are given as
the mean 6 SEM. *, p < .05; **, p < .01 versus the time-matched
LV-shRNA scramble sequence sample. Gray hatched line denotes
scramble sequence reference value. Abbreviation: SCR, scramble;
shRNA, short hairpin RNA.
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a proportion of cells that are still differentiating to a terminally
differentiated, bona ﬁde EC. Indeed, in our previous manu-
script [11], we reported that the percentage of SA461 cells
expressing both markers increased from days 14 to 21 of differ-
entiation, this is in keeping with the data produced herein. Fur-
thermore, it remains possible that we are unable to improve the
differentiation efﬁciency of SA461 hES owing to the high base
level EC differentiation efﬁciency (as determined by cells
expressing one or more EC markers and MFI values), whereas
with H1 cells there remains potential to enhance the differen-
tiation, in this instance by modulating miRNA expression. It is
therefore feasible that a ﬁnite EC differentiation capacity exists
regardless of the hES background. Therefore, we suggest that
pluripotent stem cell lines that are more refractory to differen-
tiation protocols may beneﬁt from the modulation of miRNAs
to enhance the differentiation efﬁciency, but this requires anal-
ysis in other lines for conﬁrmation. In addition, we observed
signiﬁcantly improved therapeutic angiogenesis in a mouse
model of peripheral ischemia after transplantation of hESC-
ECs differentiated for 14 days, which overexpressed either
miR-99b or -181b but interestingly not miR-181a (Fig. 7).
This miRNA-mediated increase in neoangiogenesis efﬁciency
may be a combination of a direct cell effect of transplanted
cells and miR-mediated proangiogenic paracrine mechanisms.
These results show that overexpression of each of the individ-
ual miRNAs is capable of enhancing the vascular endothelial
phenotype but not all will evoke a signiﬁcant response at
transcript, protein, and functional level, indicating that their
modus operandi in EC biology is considerably complex.
Knockdown studies also failed to elucidate the role of miR-
99b, -181a, and -181b, with a signiﬁcant reduction observed
in vascular endothelial markers at the transcript level and a
reduction in NO production, but no effect on the cell popula-
tion expressing endothelial marker proteins (Supporting Infor-
mation Fig. S5).
Previous studies have not provided evidence for a single
miRNA possessing a pivotal role in the governance of EC
fate decisions despite the demonstration of differentially
expressed miRNAs during endothelial differentiation in vitro
[24, 25]. We postulate that cell speciﬁcation during the later
Figure 7. Overexpression of miRNAs improves therapeutic angiogenesis. (A): Ischemic to contralateral blood ﬂow ratio at 7, 14, and 21 days
after injection of cells in the ischemic adductor muscle. (B): Photographs show typical laser Doppler images of blood ﬂow captured from human
embryonic stem cell-endothelial cell (GFP, miR-99b, -181a, and -181b overexpression groups)-injected mice at 21 days after induction of ische-
mia. The squares highlight the areas of interest (feet), where blood ﬂow was calculated to determine the ischemic/contralateral ratio. Color scale
from blue to red indicates progressive increases in blood ﬂow. (C): Capillary density of ischemic adductor muscle (21 days postischemia). Capil-
lary density is expressed as the number of capillaries to myoﬁber ratio. Data are mean 6 SEM; *, p < .05 versus control GFP expressing virus.
Abbreviation: GFP, green ﬂuorescent protein.
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stages of development may be controlled by miRNAs. For
instance, miR-126 is not required for endothelial differentia-
tion [27] but has been reported to inhibit erythropoiesis in
CD34þ cells retaining the potential to develop toward either
EC lineage or hematopoietic cell lineage [51], indicating miR-
NAs may negatively regulate further lineage speciﬁcation.
This has also recently been demonstrated in ECs, with miR-
181a reported to directly target Prox1, the key regulator of
lymphatic EC identity, [56, 57] and miR-181a overexpression
directing lymphatic ECs toward a blood vascular phenotype
[50].
This is in agreement with the data presented herein, with
miR-181a knockdown inducing expression of Prox1 and over-
expression augmenting the expression of the arterial-speciﬁc
genes, EphrinB1, EphrinB2, Jagged2, and Hey2 [58], and in-
hibiting the expression of Prox1 [56] (Fig. 6). This increase in
arterial gene expression is perhaps surprising considering that
we observed no signiﬁcant improvement in therapeutic angio-
genesis with miR-181a overexpressing hES-ECs. Overexpres-
sion and knockdown strategies for miR-99b and -181b failed
to determine a similar pattern; however, speculatively, it is
possible that these miRs may be more involved in the function
of hES-ECs. We observe improvement in hES-EC NO produc-
tion at later differentiation time points for overexpression of
miR-99b and -181b than for -181a (Fig. 5). This may in turn
elicit a more potent response in vivo, potentially accounting
for the increased improvement in neoangeogenesis. Equally, it
remains possible that the expression of these miRNAs is
increased as a consequence of endothelial differentiation, as
opposed to their expression governing differentiation, and that
their role in cell speciﬁcation remains to be fully elucidated.
To understand the functional role of these or any subsequently
identiﬁed miRNAs in endothelial fate determination, it will be
necessary to identify and validate target genes involved in de-
velopmental speciﬁcation. There are several predicted targets
for miRNAs miR-99b, -181a, and -181b; however, most of
these targets have not been experimentally validated. Our
study is impaired toward identifying targets of miR-99b,
-181a, and -181b as most of these predicted targets will not be
expressed in pluripotent, mesoderm, or ECs and their precur-
sors. It is likely that the increased expression of these and
other miRNAs serves to inhibit the induction of genes, which
may facilitate development or differentiation to alternative
germ layers or mesoderm cell lineages.
CONCLUSIONS
In conclusion, this is the ﬁrst study to demonstrate that miR-
99b, -181a, and -181b are upregulated during hESC differen-
tiation to ECs and can potentiate EC differentiation from plu-
ripotent hESCs; miR-99b and -181a/b overexpression can
improve the differentiation efﬁciency of hESC lines, which
are refractory to speciﬁed lineage differentiation and enhance
postischemic neoangiogenesis induced by hESC-ECs. Further-
more, elucidation of the role of miRNAs and the use of
miRNA signature panels in hES-EC differentiation will aid
the development of reﬁning new approaches for cardiovascu-
lar disease proﬁling and cell therapy.
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